Literature DB >> 31940667

Endoscopic sleeve gastroplasty in the management of weight regain after sleeve gastrectomy.

Diogo Turiani Hourneaux de Moura1,2, Sérgio Barrichello3, Eduardo Guimarães Hourneaux de Moura1, Thiago Ferreira de Souza4, Manoel Dos Passos Galvão Neto4, Eduardo Grecco4, Bruno Sander5, Anna Carolina Hoff6, Felipe Matz7, Flávio Ramos7, João Henrique Felício de Lima8, Leonardo Teixeira9, Victor Dib10, Marcelo Falcão11, Helmut Potti12, Giorgio Baretta8, Pichamol Jirapinyo2, Christopher C Thompson2.   

Abstract

BACKGROUND: Sleeve gastrectomy is a well-standardized surgical treatment for obesity. However, rates of weight regain after sleeve gastrectomy in long-term follow-up are relatively high. This multicenter study is the first to evaluate the use of an endoscopic sleeve gastroplasty (ESG) technique for the management of this population.
METHODS: This was a multicenter retrospective study, including patients with weight regain following sleeve gastrectomy who underwent ESG for weight loss. Primary outcomes included absolute weight loss, percent total weight loss (%TWL), change in body mass index (BMI), percent excess weight loss (%EWL) at 6 and 12 months, and safety profile. Clinical success was defined as achieving ≥ 25 % EWL at 1 year, ≤ 5 % serious adverse event (SAE) rate following society-recommended thresholds, and %TWL ≥ 10 %.
RESULTS: 34 patients underwent ESG after sleeve gastrectomy. Technical success was 100 %. At 1 year, 82.4 % and 100 % of patients achieved ≥ 10 %TWL and ≥ 25 % EWL, respectively. Mean (SD) %TWL was 13.2 % (3.9) and 18.3 % (5.5), and %EWL was 51.9 % (19.1) and 69.9 % (29.9) at 6 months and 1 year, respectively. Mean (SD) %TWL was 14.2 % (12.5), 19.3 % (5.3), 17.5 % (5.2), and 20.4 % (3.3), and %EWL was 88.5 % (52.8), 84.4 % (22.4), 55.4 % (14.8), and 47.8 % (11.2) for BMI categories of overweight and obesity class I, II, and III, respectively, at 1 year. No predictors of success were identified in the multivariable regression analysis. No SAEs were reported.
CONCLUSION: ESG appears to be safe and effective in the management of weight regain following sleeve gastrectomy. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2020        PMID: 31940667     DOI: 10.1055/a-1086-0627

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  6 in total

Review 1.  Multidisciplinary Approach for Weight Regain-how to Manage this Challenging Condition: an Expert Review.

Authors:  Maria Paula Carlin Cambi; Giorgio Alfredo Pedroso Baretta; Daniéla De Oliveira Magro; Cesar Luiz Boguszewski; Igor Braga Ribeiro; Pichamol Jirapinyo; Diogo Turiani Hourneaux de Moura
Journal:  Obes Surg       Date:  2021-01-03       Impact factor: 4.129

Review 2.  Endoscopic Evaluation and Management of Late Complications After Bariatric Surgery: a Narrative Review.

Authors:  Vivek Kumbhari; Carel W le Roux; Ricardo V Cohen
Journal:  Obes Surg       Date:  2021-07-30       Impact factor: 4.129

3.  Systematic Review of Innovation Reporting in Endoscopic Sleeve Gastroplasty.

Authors:  Andrew C Currie; Michael A Glaysher; Natalie S Blencowe; Jamie Kelly
Journal:  Obes Surg       Date:  2021-03-27       Impact factor: 4.129

Review 4.  Endoscopic therapy of weight regain after bariatric surgery.

Authors:  Milutin Bulajic; Salvatore Francesco Vadalà di Prampero; Ivo Boškoski; Guido Costamagna
Journal:  World J Gastrointest Surg       Date:  2021-12-27

5.  Status of bariatric endoscopy-what does the surgeon need to know? A review.

Authors:  Diogo Turiani Hourneaux de Moura; Anna Carolina Batista Dantas; Igor Braga Ribeiro; Thomas R McCarty; Flávio Roberto Takeda; Marco Aurelio Santo; Sergio Carlos Nahas; Eduardo Guimarães Hourneaux de Moura
Journal:  World J Gastrointest Surg       Date:  2022-02-27

Review 6.  Endoscopic Management of Weight Recurrence Following Bariatric Surgery.

Authors:  Donna Maria Abboud; Rebecca Yao; Babusai Rapaka; Rabih Ghazi; Omar M Ghanem; Barham K Abu Dayyeh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.